ArticleMikrochimica acta2026
Au-decorated NiYFe-LDH/MWCNT nanohybrid-based high-performance immunosensor for ultrasensitive electrochemical detection of cancer antigen 125.
Article in Mikrochimica acta, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Regarding the importance of early diagnosis of ovarian cancer and its progression monitoring, an ultrasensitive sandwich-type electrochemical immunosensor was developed to detect cancer antigen 125 (CA 125) biomarker. A hybrid nanocomposite was synthesized by integrating COOH-functionalized multi-walled carbon nanotubes (MWCNT-COOH) with a trimetallic NiYFe layered double hydroxide (NiYFe-LDH). To further improve the electrochemical activity, gold nanoparticles (AuNPs) were deposited onto the resulting nanohybrid structure. The final Au@LDH/MWCNT nanocomposite was characterized using standard methods and subsequently employed to modify screen-printed carbon electrodes (SPCEs) for capturing the sandwich structure of the immunosensor. The high specific surface area and biocompatibility of the nanocomposite provided an appropriate microenvironment for the effective capture of primary antibodies (Ab1) and preserving the integrity of the sandwich structure during signal analysis. The output response of the immunosensor was measured utilizing differential pulse voltammetry (DPV), revealing a wide linear range of 0.1 U mL− 1 to 600 U mL− 1 and a low detection limit of 0.0013 U mL− 1. The immunosensor demonstrated excellent selectivity, stability, and reproducibility. Furthermore, its reliable performance for the clinical applications was confirmed by evaluating recoveries using the standard addition and the standard enzyme-linked immunosorbent assay (ELISA) methods. Additionally, the results exhibited that the proposed platform can be further developed for the detection of other cancer-related biomarkers.
Indexed as
Identifiers
41731152What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.